Effect of Prevacid on Prostaglandin Levels in Patient With Stress Ulcer
1 other identifier
interventional
30
1 country
1
Brief Summary
The purpose of this study is to measure the prostaglandin levels in patients with stress ulcer and the effect of Prevacid on prostaglandin levels in patients with stress ulcer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4
Started Oct 2005
Typical duration for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2005
CompletedFirst Submitted
Initial submission to the registry
October 13, 2005
CompletedFirst Posted
Study publicly available on registry
October 17, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2007
CompletedJuly 31, 2013
July 1, 2013
1 year
October 13, 2005
July 29, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
the effect of Prevacid on prostaglandin levels at 8 weeks
8 weeks
Secondary Outcomes (1)
esophagogastroduodenal endoscopy(EGD) with biopsy at day 1; EGD with biopsy at 8 weeks
8 weeks
Study Arms (1)
Prevacid
EXPERIMENTALEffect of Prevacid at 8 weeks; EGD(esophagogastroduodenal endoscopy) at day 1 \& EGD at 8 weeks
Interventions
Effect of Prevacid on prostaglandin levels at 8 weeks; EGD (esophagogastroduodenal endoscopy) with biopsy at day 1 \& EGD with biopsy at 8 weeks
Eligibility Criteria
You may qualify if:
- Patients in ICU with documented gastric stress ulcer by endoscopic examination, including patients with H. Pylori infection;
- Patients have no known ulcer within 8 weeks prior to be admitted to ICU;
- Patients not on any PPI for 4 weeks prior to the study;
- Patients or family be consented for the study.
You may not qualify if:
- Patients have gastric ulcer within 8 weeks prior to be admitted to ICU;
- Patients have gastric cancer confirmed by pathology;
- Patients on one of the PPIs already;
- Patients on any of the Non-steroidal Antiinflammatory Drugs.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Emory Universitylead
- TAP Pharmaceutical Products Inc.collaborator
Study Sites (1)
Emory University School of Medicine
Atlanta, Georgia, 30322, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Qiang Cai, MD, PhD
Emory University
- STUDY DIRECTOR
Vincent W Yang, MD, PhD
Emory University
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
October 13, 2005
First Posted
October 17, 2005
Study Start
October 1, 2005
Primary Completion
October 1, 2006
Study Completion
December 1, 2007
Last Updated
July 31, 2013
Record last verified: 2013-07